» Articles » PMID: 37560988

Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease

Overview
Specialty Critical Care
Date 2023 Aug 10
PMID 37560988
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease is a major health problem with a high prevalence, a rising incidence, and substantial morbidity and mortality. Its course is punctuated by acute episodes of increased respiratory symptoms, termed exacerbations of chronic obstructive pulmonary disease (ECOPD). ECOPD are important events in the natural history of the disease, as they are associated with lung function decline and prolonged negative effects on quality of life. The present-day therapy for ECOPD with short courses of antibiotics and steroids and escalation of bronchodilators has resulted in only modest improvements in outcomes. Recent data indicate that ECOPD are heterogeneous, raising the need to identify distinct etioendophenotypes, incorporating traits of the acute event and of patients who experience recurrent events, to develop novel and targeted therapies. These characterizations can provide a complete clinical picture, the severity of which will dictate acute pharmacological treatment, and may also indicate whether a change in maintenance therapy is needed to reduce the risk of future exacerbations. In this review we discuss the latest knowledge of ECOPD types on the basis of clinical presentation, etiology, natural history, frequency, severity, and biomarkers in an attempt to characterize these events.

Citing Articles

The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.

Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.

PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.


Symptom Network and Subgroup Analysis in Patients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.

Yu C, Xu M, Pang X, Zhang Y, Cao X, Xu Y Int J Chron Obstruct Pulmon Dis. 2025; 20:181-192.

PMID: 39872088 PMC: 11771159. DOI: 10.2147/COPD.S498792.


Protocol for the enhanced management of multimorbid patients with COPD and severe asthma: role of indoor air quality.

Gomez-Lopez A, Arismendi E, Cano I, Farre R, Figols M, Hernandez C BMJ Open Respir Res. 2025; 12(1.

PMID: 39837595 PMC: 11752068. DOI: 10.1136/bmjresp-2024-002589.


Identification and Construction of a R-loop Mediated Diagnostic Model and Associated Immune Microenvironment of COPD through Machine Learning and Single-Cell Transcriptomics.

Lin J, Nan Y, Sun J, Guan A, Peng M, Dai Z Inflammation. 2025; .

PMID: 39798034 DOI: 10.1007/s10753-024-02232-x.


Impact of seasonal biometeorological conditions and particulate matter on asthma and COPD hospital admissions.

Romaszko-Wojtowicz A, Draganska E, Doboszynska A, Glinska-Lewczuk K Sci Rep. 2025; 15(1):450.

PMID: 39747992 PMC: 11696462. DOI: 10.1038/s41598-024-84739-9.


References
1.
Chen Y, Chen V, Hollander Z, Leipsic J, Hague C, DeMarco M . C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. PLoS One. 2017; 12(3):e0174063. PMC: 5362097. DOI: 10.1371/journal.pone.0174063. View

2.
Sato M, Chubachi S, Sasaki M, Haraguchi M, Kameyama N, Tsutsumi A . Impact of mild exacerbation on COPD symptoms in a Japanese cohort. Int J Chron Obstruct Pulmon Dis. 2016; 11:1269-78. PMC: 4907494. DOI: 10.2147/COPD.S105454. View

3.
Ceviker Y, Sayiner A . Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther. 2013; 27(2):179-83. DOI: 10.1016/j.pupt.2013.03.004. View

4.
Sadatsafavi M, Sin D, Zafari Z, Criner G, Connett J, Lazarus S . The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. Am J Epidemiol. 2016; 184(9):681-689. PMC: 5100830. DOI: 10.1093/aje/kww085. View

5.
Kerkhof M, Voorham J, Dorinsky P, Cabrera C, Darken P, Kocks J . The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline. Int J Chron Obstruct Pulmon Dis. 2020; 15:1909-1918. PMC: 7418151. DOI: 10.2147/COPD.S253812. View